Life Biosciences scores FDA approval for human rejuvenation trial: Because tech founders need to outlive their next funding round

Life Biosciences, a Boston-based startup founded by Harvard professor David Sinclair, has received FDA approval to proceed with the first human test of a rejuvenation method aimed at treating blindness. The company plans to begin the trial shortly, marking a significant milestone in the field of regenerative medicine. Sinclair, a renowned life-extension evangelist, has been at the forefront of research on aging and age-related diseases. The trial will focus on treating blindness, a condition that affects millions of people worldwide. The approval is a major breakthrough for Life Biosciences, which is working to develop innovative therapies to address age-related diseases. The company's approach involves using a novel method to rejuvenate cells, with the goal of restoring vision in individuals with blindness. The trial's outcome is expected to have significant implications for the treatment of age-related diseases, and the broader healthcare industry is closely watching the development.